1 Min Read
March 22 (Reuters) - Moleculin Biotech Inc:
* Moleculin receives Orphan Drug designation for Annamycin for the treatment of acute myeloid leukemia Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.